Abstract
Hyperlipidemia is a common cardiovascular disease characterized by elevated lipid level in association with disordered lipoproteins metabolism. Atorvastatin, an HMG-CoA reductase inhibitor, has been developed as an antihyperlipidaemic agent and proved to exhibit antioxidant activity against lipid peroxidation. The two hydroxyl metabolites of atorvastatin, Ortho-hydroxy-atorvastatin and para-hydroxy-atorvastatin, are equipotent to their parent compound. Anethol trithione is a kind of liver protecting agent used to treat the hepatobiliary disease-related symptoms. Desmethyl anethol trithione, the degradation product of anethol trithione, keeps the related activity of anethol trithione and it is suitable for developing novel prodrugs. In this letter, a series of atorvastatin derivatives was designed as lipid regulators based on the structures of para-hydroxy-atorvastatin and desmethyl anethol trithione. Preliminary biological evaluation suggested compound 11a presented promising antihyperlipidemic, antioxidant activity and plasma stability.
Keywords: Hyperlipidemia, Atorvastatin derivatives, Anethol trithione, Antihyperlipidaemic activity, Antioxidant activity, Plasma stability.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of Atorvastatin Derivatives as Novel HMG-CoA Reductase Inhibitors
Volume: 10 Issue: 9
Author(s): Jiayi Tong, Naxin Wang and Hua Xiao
Affiliation:
Keywords: Hyperlipidemia, Atorvastatin derivatives, Anethol trithione, Antihyperlipidaemic activity, Antioxidant activity, Plasma stability.
Abstract: Hyperlipidemia is a common cardiovascular disease characterized by elevated lipid level in association with disordered lipoproteins metabolism. Atorvastatin, an HMG-CoA reductase inhibitor, has been developed as an antihyperlipidaemic agent and proved to exhibit antioxidant activity against lipid peroxidation. The two hydroxyl metabolites of atorvastatin, Ortho-hydroxy-atorvastatin and para-hydroxy-atorvastatin, are equipotent to their parent compound. Anethol trithione is a kind of liver protecting agent used to treat the hepatobiliary disease-related symptoms. Desmethyl anethol trithione, the degradation product of anethol trithione, keeps the related activity of anethol trithione and it is suitable for developing novel prodrugs. In this letter, a series of atorvastatin derivatives was designed as lipid regulators based on the structures of para-hydroxy-atorvastatin and desmethyl anethol trithione. Preliminary biological evaluation suggested compound 11a presented promising antihyperlipidemic, antioxidant activity and plasma stability.
Export Options
About this article
Cite this article as:
Tong Jiayi, Wang Naxin and Xiao Hua, Synthesis and Biological Evaluation of Atorvastatin Derivatives as Novel HMG-CoA Reductase Inhibitors, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113106660020
DOI https://dx.doi.org/10.2174/15701808113106660020 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Understanding and Modulating the Toll Like Receptors (TLRs) and NOD Like Receptors (NLRs) Cross Talk in Type 2 Diabetes
Current Diabetes Reviews Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Mental Health Problems Experienced by Patients with Rheumatic Diseases During COVID-19 Pandemic
Current Rheumatology Reviews Nutritional and therapeutic approaches to modulate NADPH oxidase-derived ROS signaling in platelets.
Current Pharmaceutical Design Estriol Inhibits Dermcidin Isoform-2 Induced Inflammatory Cytokine Expression Via Nitric Oxide Synthesis in Human Neutrophil
Current Molecular Medicine Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology Prevention and Management of Hypertension Without Drugs
Current Hypertension Reviews Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites
Current Alzheimer Research Lipoprotein(a) is a Therapeutic Target for Cardiovascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Insights into the Role of HIF-1 in Cutaneous Wound Healing
Current Molecular Medicine Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Editorial: Ischemic Stroke Prevention
Current Vascular Pharmacology Review: Technegas - 99mTc-Metal Core Graphite Nanoparticles for Pulmonary Ventilation Imaging
Current Radiopharmaceuticals Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Ryanodine Receptor Patents
Recent Patents on Biotechnology